Experienced leadership in oncolytic immunotherapy development

ImmVirX has a highly skilled team with deep experience in developing oncolytic immunotherapies. Many of its directors, executives and scientific staff previously worked at Viralytics, a clinical-stage oncolytic immunotherapy company acquired by Merck & Co., Inc. for A$502 million.